Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Dolak, W; Schreiber, F; Schwaighofer, H; Gschwantler, M; Plieschnegger, W; Ziachehabi, A; Mayer, A; Kramer, L; Kopecky, A; Schrutka-Kölbl, C; Wolkersdörfer, G; Madl, C; Berr, F; Trauner, M; Püspök, A; Austrian Biliary RFA Study Group.
Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications.
Surg Endosc. 2014; 28(3):854-860
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Schreiber Florian
Trauner Michael

Dimensions Citations:

Plum Analytics:
Biliary radiofrequency ablation (RFA) using the Habib™ EndoHBP catheter is a new endoscopic palliation therapy for malignant biliary obstruction. The aim of this study was to assess the feasibility and safety of this technique. In this nationwide retrospective study of prospectively collected clinical data, all patients treated by biliary RFA in Austria between November 2010 and December 2012 were included. Procedure-related complications, adverse events within 30 days post-intervention, stent patency, and mortality rates were investigated. A total of 58 patients (31 male, 27 female, median age 75 years) underwent 84 RFA procedures at 11 Austrian referral centers for biliary endoscopy. The predominant underlying condition was Klatskin tumor (45 of 58 cases). All 84 RFA procedures were feasible without technical problems. A partial liver infarction was induced by RFA in a 49-year-old Klatskin tumor patient. During 30 days after each RFA procedure, five cases of cholangitis, three cases of hemobilia, two cases of cholangiosepsis, and one case each of gallbladder empyema, hepatic coma, and newly diagnosed left bundle branch block occurred. Median stent patency after last electively performed RFA was 170 days (95 % CI 63-277) and was almost significantly different between metal and plastic stenting (218 vs. 115 days; p = 0.051). Median survival was 10.6 months (95 % CI 6.9-14.4) from the time of the first RFA in each patient and 17.9 months (95 % CI 10.3-25.6) from the time of initial diagnosis. Except for one severe interventional complication (hepatic infarct), RFA presented as a technically feasible and safe therapeutic option for the palliative treatment of malignant biliary obstruction. The good results of stent patency and survival in this study should be proven in prospective (controlled) trials to further quantify the efficacy of this promising new technique.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Aged, 80 and over -
Animals -
Animals - epidemiology
Bile Duct Neoplasms - complications Bile Duct Neoplasms - diagnosis
Catheter Ablation - instrumentation
Cats -
Cholangiopancreatography, Endoscopic Retrograde - methods
Cholestasis - diagnosis Cholestasis - etiology Cholestasis - surgery
Equipment Design -
Female -
Follow-Up Studies -
Humans -
Incidence -
Male -
Middle Aged -
Palliative Care - methods
Postoperative Complications - epidemiology
Retrospective Studies -
Stents -
Surgery, Computer-Assisted - methods
Survival Rate - trends
Time Factors -

Find related publications in this database (Keywords)
Malignant biliary obstruction
Endoscopic radiofrequency ablation
Endoscopic retrograde cholangiopancreatography
Therapeutic endoscopy
Hilar cholangiocarcinoma
© Meduni Graz Impressum